GeneDx Holdings Corp. (WGS) FY2026 YTD Q2 Statement of Cash Flows

Statement of Cash Flows

2026-01-01 to 2026-06-30

Swipe to see the full flow
GeneDx Holdings Corp. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Proceeds from long term debt, net of issuance costs → financing reconciliation: $96,699,000.00Proceeds from issuance of common stock pursuant to employee stock purchase plan → financing reconciliation: $1,793,000.00Proceeds from issuance of common stock from subscription agreements → financing reconciliation: $476,000.00Exercise of stock options → financing reconciliation: $58,000.00financing reconciliation → Net cash from financing activities: $39,595,000.00financing reconciliation → Repayment and principal payments for long-term debt - Perceptive Term Loan Facility: $54,000,000.00financing reconciliation → Repayment and principal payments for long-term debt - DECD Loan Agreement: $4,447,000.00financing reconciliation → Finance lease principal payments: $984,000.00Proceeds from maturities of marketable securities → investing reconciliation: $20,475,000.00Proceeds from sales of marketable securities → investing reconciliation: $2,272,000.00investing reconciliation → Purchases of marketable securities: $29,065,000.00investing reconciliation → Purchases of property and equipment and development of internal-use software: $16,567,000.00Net cash used in operating activities → operating reconciliation: $61,389,000.00Impairment loss → operating reconciliation: $31,287,000.00Stock-based compensation expense → operating reconciliation: $15,338,000.00Depreciation and amortization expense → operating reconciliation: $13,523,000.00Loss on extinguishment of debt → operating reconciliation: $6,565,000.00Other → operating reconciliation: $2,157,000.00Deferred tax expense → operating reconciliation: $379,000.00operating reconciliation → Net (loss) income: $81,056,000.00operating reconciliation → Other assets and liabilities: $20,021,000.00operating reconciliation → Accounts payable and accrued expenses: $12,566,000.00operating reconciliation → Accounts receivable: $9,240,000.00operating reconciliation → Inventory: $3,973,000.00operating reconciliation → Change in fair value of financial liabilities: $2,760,000.00operating reconciliation → Change in third party payor reserves: $1,022,000.00Net cash used in investing activities → investing reconciliation: $22,885,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $105,989,000.00Net cash from financing activities → Cash sources and uses: $39,595,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $61,310,000.00Cash sources and uses → Net cash used in investing activities: $22,885,000.00Cash sources and uses → Net cash used in operating activities: $61,389,000.00Depreciation and amortization expense: $13,523,000.00D&A and accretion+$13.52 MStock-based compensation expense: $15,338,000.00Stock-based compensation+$15.34 MChange in fair value of financial liabilities: -$2,760,000.00Warrant fair value−$2.76 MDeferred tax expense: $379,000.00Deferred taxes & credits+$379.00 KOther: $2,157,000.00Other operating, net+$2.16 MAccounts payable and accrued expenses: -$12,566,000.00Payables & accrued liabilities−$12.57 MImpairment loss: $31,287,000.00Asset impairments+$31.29 MNet (loss) income: -$81,056,000.00Net (loss) income−$81.06 MChange in third party payor reserves: -$1,022,000.00Third-party payor reserves−$1.02 MLoss on extinguishment of debt: $6,565,000.00Debt extinguishment gain & loss+$6.57 MAccounts receivable: -$9,240,000.00Accounts receivable−$9.24 MInventory: -$3,973,000.00Inventories−$3.97 MOther assets and liabilities: -$20,021,000.00Other working capital, net−$20.02 MNet cash used in operating activities: -$61,389,000.00. Cash required to fund net payments.Operating cash−$61.39 Moperating reconciliation: $130,638,000.00Proceeds from long term debt, net of issuance costs: $96,699,000.00Long-term debt issued+$96.70 MProceeds from offerings, net of issuance costs: $0.00Proceeds from issuance of common stock from subscription agreements: $476,000.00Common stock issued+$476.00 KProceeds from issuance of common stock pursuant to employee stock purchase plan: $1,793,000.00Employee stock plan proceeds+$1.79 MExercise of stock options: $58,000.00Stock option exercises+$58.00 KRepayment and principal payments for long-term debt - DECD Loan Agreement: -$4,447,000.00DECD loan repaid−$4.45 MRepayment and principal payments for long-term debt - Perceptive Term Loan Facility: -$54,000,000.00Perceptive term loan repaid−$54.00 MFinance lease principal payments: -$984,000.00Finance lease payments−$984.00 KNet cash from financing activities: $39,595,000.00Financing cash+$39.60 Mfinancing reconciliation: $99,026,000.00Acquisition of business, net of cash acquired: $0.00Purchases of marketable securities: -$29,065,000.00Marketable securities purchases−$29.07 MProceeds from sales of marketable securities: $2,272,000.00AFS securities sales+$2.27 MProceeds from maturities of marketable securities: $20,475,000.00AFS securities maturities+$20.48 MPurchases of property and equipment and development of internal-use software: -$16,567,000.00PP&E purchases−$16.57 MNet cash used in investing activities: -$22,885,000.00. Cash required to fund net payments.Investing cash−$22.89 Minvesting reconciliation: $45,632,000.00Cash sources and uses: $145,584,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $105,989,000.00Beginning cash$105.99 MEnding cash: Cash, cash equivalents, and restricted cash: $61,310,000.00Ending cash$61.31 MCASH RECONCILIATIONFinancingflowsInvestingflowsOperatingflowsNet loss −$81.06M + net operating adjustments $19.67M = operating cash −$61.39MFree cash flow−$77.96 MOperating cash − cash spent on PP&ECash flow / Net incomeNot meaningfulOperating cash flow ÷ net incomeNet cash change−$44.68 MEnding cash − beginning cash
Chart details

GeneDx Holdings Corp. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026

Cash flows for Jan 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2025. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2025
105,989,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
negative 61,389,000 US dollars. Net cash used.
Net (loss) income
negative 81,056,000 US dollars
Depreciation and amortization expense
13,523,000 US dollars
Stock-based compensation expense
15,338,000 US dollars
Change in fair value of financial liabilities
negative 2,760,000 US dollars
Deferred tax expense
379,000 US dollars
Other
2,157,000 US dollars
Accounts payable and accrued expenses
negative 12,566,000 US dollars
Impairment loss
31,287,000 US dollars
Change in third party payor reserves
negative 1,022,000 US dollars
Loss on extinguishment of debt
6,565,000 US dollars
Accounts receivable
negative 9,240,000 US dollars
Inventory
negative 3,973,000 US dollars
Other assets and liabilities
negative 20,021,000 US dollars
Investing activities
negative 22,885,000 US dollars. Net cash used.
Acquisition of business, net of cash acquired
0 US dollars
Purchases of marketable securities
negative 29,065,000 US dollars
Proceeds from sales of marketable securities
2,272,000 US dollars
Proceeds from maturities of marketable securities
20,475,000 US dollars
Purchases of property and equipment and development of internal-use software
negative 16,567,000 US dollars
Financing activities
39,595,000 US dollars. Net cash provided.
Proceeds from long term debt, net of issuance costs
96,699,000 US dollars
Proceeds from offerings, net of issuance costs
0 US dollars
Proceeds from issuance of common stock from subscription agreements
476,000 US dollars
Proceeds from issuance of common stock pursuant to employee stock purchase plan
1,793,000 US dollars
Exercise of stock options
58,000 US dollars
Repayment and principal payments for long-term debt - DECD Loan Agreement
negative 4,447,000 US dollars
Repayment and principal payments for long-term debt - Perceptive Term Loan Facility
negative 54,000,000 US dollars
Finance lease principal payments
negative 984,000 US dollars
Operating adjustment reconciliation
130,638,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
99,026,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
45,632,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
0 US dollars
Ending cash on Jun 30, 2026
61,310,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
145,584,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
negative 44,679,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
Operating cash flow
negative 61,389,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
16,567,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
negative 77,956,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net loss −$81.06M + net operating adjustments $19.67M = operating cash −$61.39M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: negative 61,389,000 US dollars minus 16,567,000 US dollars equals negative 77,956,000 US dollars.
GeneDx Holdings Corp. (WGS) FY2026 YTD Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!